Category Archives: News

Carlyle to Announce Second Quarter 2025 Financial Results and Host Investor Conference Call

Carlyle

Washington, D.C. and New York – The Carlyle Group Inc. (NASDAQ: CG) announced today that it will release financial results for the second quarter 2025 on Wednesday, August 6, 2025, and host a conference call at 8:30 a.m. EDT. The conference call will be available via public webcast from the Events & Presentations section of ir.carlyle.com and a replay will also be available after the call’s completion.

Chief Executive Officer Harvey Schwartz, along with Chief Financial Officer and Head of Corporate Strategy John Redett and Head of Public Market Investor Relations Daniel Harris, will review the results during the call.

The earnings release will be available through all Carlyle channels, including the Earnings Releases section of ir.carlyle.com and the firm’s X and LinkedIn accounts.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $453 billion of assets under management as of March 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents.

Contacts
Public Market Investor Relations
Daniel Harris
+1 (212) 813-4527
daniel.harris@carlyle.com

Media
Brittany Berliner
+1 (212) 813-4839
brittany.berliner@carlyle.com

OR

Kristen Ashton
+1 (212) 813-4763
kristen.ashton@carlyle.com

Categories: News

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

No Comments
Abingworth
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Merck to hold investor call at 8 a.m. ET today

RAHWAY, N.J. & RALEIGH, N.C.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

Through this acquisition Merck will add Ohtuvayre® (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and portfolio. The U.S. Food and Drug Administration approved Ohtuvayre in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first novel inhaled mechanism for the treatment of COPD in more than 20 years and combines bronchodilator and non-steroidal anti-inflammatory effects. Ohtuvayre is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis.

“This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ability to execute on our science-led and value-driven business development strategy,” said Robert M. Davis, chairman and chief executive officer, Merck. “Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders. This novel, first-in-class treatment addresses an important unmet need for COPD patients persistently symptomatic based on its unique combination of bronchodilatory and non-steroidal anti-inflammatory effects. We look forward to welcoming the talented Verona Pharma team to Merck.”

“Today’s announced agreement with Merck is the culmination of years of focus and determination by the Verona Pharma team advancing Ohtuvayre, the first novel inhaled mechanism for the maintenance treatment of COPD in two decades,” said David Zaccardelli, president and chief executive officer, Verona Pharma. “Since launching Ohtuvayre in August 2024 we have seen rapid and accelerating uptake in the U.S. We believe Merck’s commercial footprint and industry-leading clinical capabilities will help accelerate the potential of Ohtuvayre to reach more patients living with COPD. This agreement will enable the strong launch trajectory of this important medicine and provides value to Verona Pharma shareholders.”

The transaction was unanimously approved by both the Merck and Verona Pharma Boards of Directors and is intended to be effected by way of a scheme of arrangement under UK law. Closing of the proposed acquisition is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, approval of Verona Pharma shareholders, sanction by the High Court of Justice of England and Wales and other customary conditions. The transaction is expected to close in the fourth quarter of 2025 and will result in the capitalization of most of the purchase price as an intangible asset for Ohtuvayre (which will be amortized as a GAAP-only charge over the life of the product).

Investor Call

Merck will hold an investor call today, July 9, 2025 at 8 a.m. ET to discuss the proposed transaction. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call. Investors, journalists and the general public may access a live audio webcast of the call via this weblink.

All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 2398172.

Advisors

Citi and Morgan Stanley & Co. LLC acted as financial advisors to Merck in this transaction and Freshfields LLP acted as Merck’s legal advisor. Centerview Partners LLC acted as exclusive financial advisor to Verona Pharma and Latham & Watkins LLP as Verona Pharma’s legal advisor.

Ohtuvayre Indication and Important Safety Information

INDICATION

Ohtuvayre is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.

IMPORTANT SAFETY INFORMATION

Contraindication: Ohtuvayre is contraindicated in patients with hypersensitivity to ensifentrine or any component of this product.

Warnings and Precautions:

Acute Episodes of Bronchospasm Ohtuvayre should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting bronchodilator.

Paradoxical Bronchospasm As with other inhaled medicines, Ohtuvayre may produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with Ohtuvayre, it should be treated immediately with an inhaled, short-acting bronchodilator. Ohtuvayre should be discontinued immediately and alternative therapy should be instituted.

Psychiatric Events Including Suicidality Before initiating treatment with Ohtuvayre, healthcare providers should carefully weigh the risk and benefits of treatment with Ohtuvayre in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes, and if such changes occur to contact their healthcare provider. Healthcare providers should carefully evaluate the risks and benefits of continuing treatment with Ohtuvayre if such events occur.

Treatment with Ohtuvayre is associated with an increase in psychiatric adverse reactions. Psychiatric events including suicide-related adverse reactions were reported in clinical studies in patients who received Ohtuvayre (1 suicide attempt and 1 suicide). Additionally, the most commonly reported psychiatric adverse reactions in the pooled 24-week safety population were insomnia (6 patients [0.6%] Ohtuvayre 3 mg; 2 patients [0.3%] placebo), and anxiety (2 patients [0.2%] Ohtuvayre 3 mg; 1 patient [0.2%] placebo). Depression-related reactions including depression, major depression, and adjustment disorder with depressed mood occurred in 4 patients [0.4%] receiving Ohtuvayre and no patients receiving placebo.

Adverse Reactions: The most common adverse reactions ≥1% in Ohtuvayre and greater than placebo in the pooled population were back pain 1.8%, hypertension 1.7%, urinary tract infection 1.3%, and diarrhea 1.0%.

These are not all of the possible risks associated with Ohtuvayre.

Please see Prescribing Information for Ohtuvayre (ensifentrine) at: https://ohtuvayrehcp.com/wp-content/uploads/sites/2/2024/11/Ohtuvayre-US-Prescribing-Information.pdf, Patient Information for Ohtuvayre at: https://ohtuvayre.com/wp-content/uploads/2024/11/Ohtuvayre-US-Prescribing-Information.pdf.

About Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that causes restricted airflow and breathing problems. Emphysema and chronic bronchitis are the two most common types of COPD. Common symptoms of COPD include shortness of breath an ongoing cough or a cough that produces a lot of mucus, wheezing, chest tightness or heaviness and fatigue. Smoking and air pollution are the most common causes of COPD. An estimated 390 million people suffer from COPD worldwide as of 2019 and COPD is the fourth leading cause of death worldwide. There is no cure for COPD.

About Ohtuvayre® (ensifentrine)

Ohtuvayre is the first inhaled therapy for the maintenance treatment of adults with COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function. A fixed-dose combination of ensifentrine and glycopyrrolate, a LAMA, is currently under development for the maintenance treatment of COPD.

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. For more information, please visit www.veronapharma.com.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

UK Takeover Code does not apply

Verona Pharma is not a company subject to regulation under the City Code on Takeovers and Mergers (the “UK Takeover Code”), therefore no dealing disclosures are required to be made under Rule 8 of the UK Takeover Code by shareholders of Verona Pharma or Merck.

Additional Information and Where to Find it

In connection with the proposed transaction between Verona Pharma and Merck, Verona Pharma will file with the Securities and Exchange Commission (“SEC”) a proxy statement on Schedule 14A. Additionally, Verona Pharma may file other relevant materials with the SEC in connection with the proposed transaction. Investors and securityholders of Verona Pharma are urged to read the proxy statement (which will include an explanatory statement in respect of the Scheme of Arrangement of Verona Pharma, in accordance with the requirements of the U.K. Companies Act 2006) and any other relevant materials filed or that will be filed with the SEC, as well as any amendments or supplements to these materials and documents incorporated by reference therein, carefully and in their entirety when they become available because they contain or will contain important information about the proposed transaction and related matters. The definitive version of the proxy statement will be mailed or otherwise made available to Verona Pharma’s securityholders. Investors and securityholders will be able to obtain a copy of the proxy statement (when it is available) as well as other filings containing information about the proposed transaction that are filed by Verona Pharma or Merck with the SEC, free of charge on EDGAR at www.sec.gov, on the investor relations page of Verona Pharma’s website at https://www.veronapharma.com/investors/, by contacting Verona Pharma’s investor relations department at IR@veronapharma.com, or on Merck’s website at www.merck.com.

Participants in the Solicitation

Verona Pharma, Merck and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Verona Pharma in connection with the proposed transaction. Information about Verona Pharma’s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, will be included in the proxy statement (when available). You may also find additional information about Verona Pharma’s directors and executive officers in Verona Pharma’s proxy statement for its 2025 Annual General Meeting filed on March 18, 2025 and Verona Pharma’s other filings with the SEC available at the SEC’s Internet site (www.sec.gov), including any statements of beneficial ownership on Form 3 or Form 4 filed with the SEC after such proxy statement. Information about Merck and its directors and executive officers can be found in Merck’s proxy statement filed on April 9, 2025 and Merck’s other filings with the SEC available at the SEC’s Internet site (www.sec.gov), including any statements of beneficial ownership on Form 3 or Form 4 filed with the SEC after such proxy statement. Verona Pharma shareholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Verona Pharma directors and executive officers in the proposed transaction, which may be different than those of Verona Pharma shareholders generally, by reading the proxy statement and any other relevant documents that are filed or will be filed with the SEC relating to the proposed transaction. You may obtain free copies of these document using the sources indicated above.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including with respect to the company’s proposed acquisition of Verona Pharma, and readers are cautioned not to place undue reliance on such statements. Such forward-looking statements include, but are not limited to, the ability of the company and Verona Pharma to complete the transactions contemplated by the transaction agreement, including the parties’ ability to satisfy the conditions to the consummation of the transaction contemplated thereby, statements about the expected timetable for completing the transaction, the company’s and Verona Pharma’s beliefs and expectations and statements about the benefits sought to be achieved in the company’s proposed acquisition of Verona Pharma, the potential effects of the acquisition on both the company and Verona Pharma, the possibility of any termination of the transaction agreement, as well as the expected benefits and success of Verona Pharma’s products and product candidates. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable or at all, or that any pipeline candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the proposed transaction; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the proposed transaction contained in the transaction agreement may not be satisfied or waived (including, but not limited to, the failure to obtain the approval of the proposed transaction by Verona Pharma shareholders and the failure to obtain the sanction of the High Court of Justice of England and Wales); the effects of disruption from the transactions contemplated by the transaction agreement and the impact of the announcement and pendency of the transactions on Verona Pharma’s business; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Forward-Looking Statements of Verona Pharma

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including with respect to the proposed acquisition of Verona Pharma, and readers are cautioned not to place undue reliance on such statements. Such forward-looking statements include, but are not limited to, the ability of Merck and Verona Pharma to complete the transactions contemplated by the transaction agreement, including statements about the transaction contemplated thereby, statements about the expected timetable for completing the transaction, Verona Pharma’s beliefs and expectations and statements about the benefits sought to be achieved in the proposed acquisition, the potential effects of the acquisition on Verona Pharma, as well as the expected benefits and success of Verona Pharma’s products and product candidates. These statements are based upon the current beliefs and expectations of Verona Pharma’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable or at all, or that any pipeline candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the proposed transaction; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the proposed transaction contained in the transaction agreement may not be satisfied or waived (including, but not limited to, the failure to obtain the approval of the proposed transaction by Verona Pharma shareholders and the failure to obtain the sanction of the High Court of Justice of England and Wales); the effects of disruption from the transactions contemplated by the transaction agreement and the impact of the announcement and pendency of the transactions on Verona Pharma’s business; the risk that shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; Verona Pharma’s dependence on the successful commercialization of Ohtuvayre and the uncertain market acceptance of Ohtuvayre as a treatment for COPD; and risks related to pharmaceutical product development, including Verona Pharma’s ongoing development of ensifentrine and any other product candidates and combinations, and the uncertainty of clinical success.

Verona Pharma undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Verona Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024 and Verona Pharma’s other filings with the SEC.

 

Contacts

Merck Investor Contact: 
Peter Dannenbaum
(732) 594-1579

Merck Media Contacts: 
Robert Josephson
(203) 914- 2372

Justine Moore
(347) 281-3754

Verona Pharma plc: 
Victoria Stewart
+1 (844) 341-9901
IR@veronapharma.com

Argot Partners: 
Verona Pharma – US Investor Enquiries 
+1 (212) 600-1902
verona@argotpartners.com

Ten Bridge Communications: 
Verona Pharma – International / US Media Enquiries 
Wendy Ryan
+1 (781) 316-4424
tbcverona@tenbridgecommunications.com

Categories: News

Tags:

Pendo Announces Acquisition of Forwrd.ai, Bringing AI-Powered Predictive Analytics into the Pendo Platform

Thomabravo

Introduces Pendo Predict to equip GTM and product teams with instant insights to drive retention, expansion and pipeline growth

RALEIGH, N.C. and TEL AVIV, ISRAEL—Pendo, the world’s first software experience management platform, today announced that it has acquired Forwrd.ai, an Israel-based no-code predictive analytics platform that empowers business leaders to build custom AI models that predict churn, upsell potential, and lead quality, without the need for data scientists or engineers.

In today’s enterprise landscape, go-to-market and product teams are inundated with vast amounts of user and behavioral data, but often lack the tools to interpret it effectively without heavy reliance on technical teams. This acquisition addresses a growing demand for more accessible, real-time insights that inform smarter business decisions.

The Forwrd technology will serve as the foundation of a new suite of AI-driven capabilities within the Pendo platform called Pendo Predict. By combining rich usage data with Forwrd’s automated models, Pendo Predict empowers cross-functional teams to proactively identify risk and opportunity—whether it’s surfacing high-intent leads for sales, detecting churn risk and suggesting customer interventions, or uncovering expansion opportunities. The result is a more agile, aligned enterprise that can act quickly on data signals to drive retention, expansion, and revenue growth.

“Usage data is the truest and most reliable signal of customer health,” said Todd Olson, CEO and co-founder of Pendo.” By integrating Forwrd’s predictive engine into the Pendo platform, we’re giving every team instant, actionable intelligence to grow revenue and eliminate churn.”

Pendo Predict includes powerful features like:

  • Churn risk modeling: Identify accounts likely to drop off—and why.
  • Lead qualification and scoring: Prioritize the prospects most likely to convert based on in-app signals.
  • Expansion opportunity detection: Spot users with high upsell potential based on feature usage momentum.
  • Predictive segmentation: Filter and target customer segments dynamically based on forecasted outcomes.
  • “Next Best Action” recommendations: Surface intelligent suggestions (e.g., launch a guide in Pendo, escalate to customer success, flag an account in Salesforce).

“From day one, our mission has been to simplify predictive AI and embed it at the core of business operations,” said Kobi Stok, CEO and founder of Forwrd. “By combining Pendo’s proprietary data and experience layer with Forwrd’s technology, we’re transforming product, marketing, and CRM data into actions that empower teams across the organization and enable hyper-personalized customer experiences.”

Stok is an experienced product executive and serial entrepreneur who founded Forwrd.ai in 2021 and built strong early traction with industry leaders like SAP, Hubspot, JFrog and AppsFlyer. Stok and team will join Pendo’s Herzilya, Israel office.

Pendo announced the acquisition during its Pendomonium X event in Munich. The news follows a series of recent product releases that help teams measure the performance of AI agents, improve user onboarding, cut support costs, increase upsell revenue, and drive team productivity.

About Pendo:

At Pendo, we’re on a mission to improve the world’s experience with software. Thousands of global companies use Pendo to provide better software experiences for 900 million people every month. Pendo improves business outcomes by enabling non-engineers to analyze, assess, and act on software issues. Our integrated Software Experience Management (SXM) platform manages the entire enterprise software asset: Customer- and employee-facing applications; desktop and mobile platforms; and SaaS, AI and Agentic software. Find out more at pendo.com.

Read the release on the Pendo website here.

Categories: News

Tags:

Carlyle Provides Financing to Support TPG’s $1.1 Billion Carve-Out of Sabre’s Hospitality Solutions Business

Carlyle

New York, NY – July 8, 2025 – Global investment firm Carlyle (NASDAQ: CG) today announced that its Global Credit platform has led a $400 million financing to support TPG’s recently completed acquisition of Sabre Corporation’s Hospitality Solutions (“Hospitality Solutions”) business. The transaction established Hospitality Solutions as an independent hospitality technology company.

Hospitality Solutions provides software and solutions to more than 40% of the world’s leading hotel brands. The SaaS based platform serves as an integrated system of record for reservation and guest information, enabling hoteliers to operate with greater accuracy and efficiency.

Carlyle’s financing will support TPG’s investment in the newly independent business as it accelerates growth, executes on new product development initiatives, and continues the onboarding of major global customers.

“We’re proud to support TPG in establishing Hospitality Solutions as an independent technology leader with a strong foundation and clear path for growth,” said Kunal Gulati, Deputy Chief Investment Officer of Carlyle Direct Lending. “This transaction reflects our ability to deliver tailored capital solutions at scale to support our partner sponsors and management teams leading strategic transformations.”

Carlyle’s Global Credit platform manages $199 billion in assets under management, as of March 31, 2025. It regularly pursues investments in privately negotiated debt and capital solutions partnering with high-quality sponsors and leading family or entrepreneur-owned companies.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

Media Contact:

Kristen Ashton
+1 212-813-4763
kristen.ashton@carlyle.com

Categories: News

Tags:

CVC Foundation announces new UK grants to advance youth opportunity

CVC Capital Partners

The CVC Foundation has announced strategic new grants to three UK-based charities: Resurgo Trust, AllChild and Greenhouse Sports.

Aligned with the Foundation’s pillars of Education, Employability, Entrepreneurship, and Venture Philanthropy, the funding supports scalable, community-led initiatives that deliver measurable, long-term impact and is part of CVC Foundation’s commitment to empowering young people and helping tackle socio-economic barriers to success.

Each partnership reflects the Foundation’s commitment to backing scalable solutions that create lasting change where it is needed most.

  • Resurgo Trust will use the funding to expand its Spear Programme, a 12-month employability initiative for 16–24-year-olds not in education, employment, or training (NEET) and face significant barriers. To date they have worked with over 11,000 young people and 75% of those who complete the programme, move into education or employment within a year of completion.
  • AllChild will grow its Impact Programme, which places Link Workers (trusted adults) in schools to deliver personalized plans of support and opportunity to children and young people at a tipping point of need, to enable them to build the social,  emotional and academic skills they need to flourish. Currently reaching c.1,700 children annually in West London and Wigan, the initiative mobilises communities to deliver a connected ecosystem of support between schools, families, local organisations and support services.
  • Greenhouse Sports will place a full-time Coach-Mentor at a Westminster secondary school. Through structured sports, mentoring, and enrichment, the programme will support over 120 students in building resilience and life skills.

Commenting on the announcement, Kate Butchart, Director of the CVC Foundation, said: “We are delighted to support organisations that are making a tangible, lasting difference in the lives of young people across the UK. By investing in scalable, community-led programmes with a proven track record, we’re helping to create meaningful pathways to opportunity. These partnerships also open up valuable opportunities for our colleagues to contribute directly whether through volunteering, mentoring, or broader engagement.”

Quotes

We are delighted to support organisations that are making a tangible, lasting difference in the lives of young people across the UK.

Kate ButchartDirector of the CVC Foundation

The new grants reaffirm the Foundation’s mission to unlock potential and drive systemic change through collaborative, grassroots solutions.

Categories: News

Tags:

Itaú Asset Management and KKR form Exclusive Strategic Partnership in Brazil to Broaden Private Market Investment Opportunities in Latin America’s Largest Market

KKR

São Paulo and New York, July 8, 2025 – Itaú Asset Management, one of the largest asset managers in Brazil, and KKR, a leading global investment firm, have formed an exclusive strategic partnership to expand private market investment opportunities for investors in Brazil. Under the agreement, KKR will serve as the preferred global alternative asset manager partner for Itaú, while Itaú will become the preferred Brazilian asset manager partner for KKR. The agreement will leverage both parties’ expertise and resources to expand their reach and competitiveness with respect to Brazil.

Itaú Asset Management is one of the leading asset management firms in Brazil with US $198 billion in Assets under Management (AUM)[1], and fully owned by Itaú Unibanco, Latin America’s largest bank, with more than a hundred-year history of serving clients. KKR is a pioneer in private markets investment with a global footprint and proven track record, managing US $664 billion in AUM[2] across alternative asset classes including private equity, credit and real assets.

Partnership Built to Scale

 

Itaú and KKR will collaborate in Latin America’s largest market to develop and provide alternative investment solutions for institutional and private wealth clients across private market asset classes. As part of this agreement, the firms will build co-branded investment products for the Brazilian market. This exclusive partnership includes the opportunity for Itaú to market KKR’s product offerings and collaborate in the development of private market investor educational materials. By leveraging their combined expertise, resources and distribution channels, the firms will enhance their reach and competitiveness in the growing market for alternative investments in what is the world’s ninth largest economy.

Globally, the alternatives industry is expected to grow to US $24 trillion in assets in 2028 from US $15 trillion in 2022 [3]. The two firms expect the private market investment sector will also continue to grow in Brazil, where Itaú has already built one of the largest alternatives platforms in both the country and Latin America. The firm has successfully created a multi-strategy platform that currently manages US $14.8 billion in AUM[4], primarily focused on private credit, liquid and illiquid alternatives strategies. As part of the agreement, Itaú Asset Management will be able to leverage KKR’s commercial and investment expertise as it continues to scale its private markets platform for investors in the region. In addition, KKR will introduce Itaú to its global network of institutional investors interested in Latin America, fostering new relationships and investment opportunities. The firms will engage in knowledge-sharing initiatives, allowing Itaú’s investment professionals to gain insights into KKR’s global investment strategies and best practices in the private markets sector. The firms also have the option to partner up in co-investments opportunities.

Client-Focused Commitment

“We are pleased to partner with Itaú, the largest and most valuable brand in Brazil, with whom we share complementary strengths and a dedicated commitment to delivering exceptional value to our clients,” said Eric Mogelof, Partner and Head of Global Client Solutions at KKR. “Itaú Asset Management is known for its outstanding investment capabilities and deep client relationships. We look forward to expanding private market investment opportunities for investors in Brazil with Itaú Asset Management in a market that is relatively new to KKR, as well as enhancing international investor access for alternative investment solutions.”

“We are thrilled to partner with KKR, a true innovator and pioneer in the asset management industry with a dedicated focus like Itaú on creating long term value for our institutional and private wealth clients. We have already built up one of the largest alternatives platforms in Brazil, and now with the support of a leading global firm such as KKR, we can further scale our business locally and internationally,” said Carlos Augusto Salamonde, Partner and Head of Global Asset Management at Itaú. “The strategic collaboration will enhance Itaú’s capacity to offer premier global alternatives solutions for our clients. There is significant growth potential for the internationalization of the portfolios of Brazilians as historically most capital has been invested domestically, with international alternatives being notably underpenetrated.”

Monica Mandelli, Managing Director, Global Client Solutions for KKR, stated: “The Brazilian asset management industry has doubled over the last five years, growing at a CAGR of 13%[5], with private bank clients materially increasing their allocation to alternatives. We see significant opportunity to grow this market with Itaú.”

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Itaú Unibanco Asset Management

Itaú Unibanco Asset Management (IAM) is a leading Brazilian-based global asset manager and a division of Itaú Unibanco, one of the largest banks in Latin America. IAM’s roots trace back to 1957 when it launched Brazil’s first equity mutual fund. With more than 65 years of history, IAM remains at the forefront of the Latin American financial sector with US $198 billion in AUM across a complete platform of products, including ETF and other listed funds, fixed income and private credit products, as well as a multi-strategy platform with more than 120 portfolio managers. IAM has offices in Sao Paulo, Rio de Janeiro, New York, Miami and Santiago.

Media Contacts:

For Itaú Unibanco Asset Management

imprensa@itau-unibanco.com.br

For KKR:

Kenny Juarez

(212) 750-8300

media@kkr.com

 

Download PDF

 

Categories: News

Tags:

Coller Capital Raises Record $6.8 Billion for Private Credit Secondaries Platform

Coller Capital

  • The landmark closing of Coller Credit Opportunities II underscores Coller Capital’s leadership and scale in private credit secondaries
  • CCO II targets senior direct lending and performing credit investments, pursuing opportunities across both LP-led and GP-led secondary transactions
  • To date the firm has now committed $10.1bn to credit secondaries

London and New York, 8 July 2025 – Coller Capital, the world’s largest dedicated private market secondaries manager, today announces the final closing of Coller Credit Opportunities II (“CCO II”), bringing a record total of $6.8 billion raised for Coller’s credit platform in its latest fundraising cycle. Coller’s credit platform includes commingled funds, co-investment vehicles, separately managed accounts, and its credit-focused perpetual funds.

The successful capital raise follows the firm’s pioneering $1.4 billion first credit fund, CCO I, which previously set the benchmark as the largest private credit secondaries fund at the time. Coller Capital’s robust fundraising reflects its established global presence, innovative approach, and deep specialist expertise in secondaries.

CCO II targets senior direct lending and high-quality performing credit investments across LP-led and GP-led opportunities. The fund seeks to deliver strong risk-adjusted returns and stable, resilient performance through market cycles by providing investors diversified exposure to premium credit assets.

The private credit secondaries market has grown substantially, driven by increasing investor demand for liquidity solutions, diversification, and sophisticated portfolio management tools. Coller Capital has seen $53bn of secondary credit investment opportunities since January 2024, with substantial growth anticipated as more private credit funds mature.

Michael Schad, Partner, Head of Coller Credit Secondaries, said: “This record-setting fundraise reinforces Coller Capital’s status as the preeminent investor in private credit secondaries. Our disciplined, credit-centric investment strategy, combined with our ability to execute complex transactions at scale, continues to resonate with global investors seeking defensive, diversified strategies. With increased market participation and liquidity demand, we anticipate continued strong activity in LP-led and GP-led transactions throughout 2025 and beyond.”

Jeremy Coller, Chief Investment Officer and Managing Partner of Coller Capital, commented: “Coller Credit Opportunities II is a milestone fundraise that reaffirms the significant evolution and maturation of the private credit secondaries market. Investors increasingly recognize the strategic importance of private credit secondaries in achieving defensive exposure, liquidity, and enhanced portfolio management amid heightened market volatility. Coller Capital’s global platform, specialist knowledge, and proven track record uniquely position us as the partner of choice for investors around the world.

“The success of this fundraise is a testament to the quality of Coller’s entire global team and the trust our partners place in us, as well as the track record of our credit leaders Michael Schad, Ed Goldstein, and Martins Marnauza who have been investing together for more than 14 years.”

Coller Capital was an early mover in credit secondaries, pioneering investments as early as 2008. To date the firm has now committed $10.1bn to the space.

Coller Capital’s leading market position is exemplified by recent landmark transactions, including the acquisition of a $1.6 billion senior direct lending portfolio from American National, one of the largest-ever LP-led credit secondaries transactions. Additionally, in 2024, Coller Capital created the industry’s largest credit continuation vehicle to date, underwriting a $1.6bn portfolio managed by Abry Partners.

Mentions
Black and white formal headshot of Michael Schad.

Michael Schad

Partner, Head of Coller Credit Secondaries
Black and white formal headshot of Ed Goldstein.

Ed Goldstein

Partner, CIO of Coller Credit Secondaries
Black and white formal headshot of Martins Marnauza.

Martins Marnauza

Partner, Investment
Black and white formal headshot of Jeremy Coller.

Jeremy Coller

Chief Investment Officer and Managing Partner
Press contact
Edelman Smithfield

coller@edelmansmithfield.com+44 (0)7980 684 247

Categories: News

Tags:

A-LIGN announces strategic investment from Hg to accelerate its global expansion

HG Capital

Partnership with Hg will accelerate A-LIGN’s growth trajectory and support its mission to become the global cyber compliance services champion.

TAMPA, FLORIDA, July 8th: A-LIGN, a leading provider of technology-enabled cybersecurity compliance services, today announces that it has secured a significant strategic investment from Hg, a leading investor in European and transatlantic software and services businesses. Hg will acquire a majority stake in the company from Warburg Pincus.

The investment comes as organizations face a surge in cyber-attacks, with AI-powered threats making compliance and security more critical and complex than ever before. This has increased the demand for sophisticated compliance partners to navigate this environment and provide assurance to stakeholders.

Headquartered in Tampa, Florida, A-LIGN’s cybersecurity compliance audits and related assessments allow organizations to provide assurances to their customers that sensitive data is protected, and that mission-critical operations are conducted with integrity.

Since its founding in 2009, A-LIGN has established itself as a category leader in cybersecurity compliance services, serving over 5,700 clients with audits and assessments including SOC 2, ISO, HITRUST, FedRAMP, CMMC and PCI standards.

A-LIGN’s customer-first approach and extensive use of technology has enabled the firm to deliver over 50% compounded annual growth over the past 15 years. A-LIGN’s delivery model combines deep domain expertise with proprietary technology, to deliver superior audit quality, while driving operational efficiency for its customers.

The partnership with Hg will support A-LIGN’s ambitious growth plans, leveraging Hg’s extensive network to accelerate its global expansion, and building on Hg’s commitment and expertise in data and AI to drive significant value for A-LIGN’s customers.

Scott Price, CEO of A-LIGN, commented: “This new partnership comes at the perfect time as we enter our next phase of growth. Hg’s deep expertise and track record in scaling tech-enabled services businesses globally, combined with world-class operational resources, makes them the ideal partner to help us provide the best possible services to our customers. I’d also like to thank Warburg Pincus and FTV Capital for their support over the last few years, in helping us reach this milestone.”

Hector Guinness and Joris van Gool, Partners at Hg: “Scott and his world-class team have built an exceptional and truly client-centric business. We have been particularly impressed by their unwavering commitment to quality, while leveraging proprietary technology to drive efficiency for their customers. This combination has created a sustainable source of competitive differentiation that we believe can extend A-LIGN’s growth in new regions, adjacent service lines, and new customer groups.”

William Holmes, Principal at Hg, added: “A-LIGN has all the hallmarks of what Hg looks for in tech-enabled services investments, and we are excited to support Scott and his world-class team to become the global champion in cyber compliance services.”

Brian Chang, Managing Director at Warburg Pincus, said: “It has been a privilege to support Scott and the talented team at A-LIGN through an exceptional period of transformative growth, partnering closely with them to expand the company’s service offerings and grow its customer base. A-LIGN is a strong example of our firm’s focus on accelerating the success of innovative market leaders in cybersecurity and compliance, especially as the number of cyber-attacks continue to rise and compliance and security needs become more complex. We wish Scott and the A-LIGN team the best in their next chapter and look forward to the company’s continued success.”

Jefferies LLC served as lead financial advisor and Guggenheim Securities, LLC served as financial advisor to A-LIGN and Warburg Pincus. Cleary Gottlieb Steen & Hamilton LLP served as legal counsel for A-LIGN and Warburg Pincus. Harris Williams served as financial advisor to Hg, with Latham & Watkins serving as Hg’s legal counsel.

For further information, please contact:

A-LIGN
Press inquiries, press@a-lign.com

Hg
Tom Eckersley, tom.eckersley@hgcapital.com
Sam Ferris, sam.ferris@hgcapital.com

Warburg Pincus
Kerrie Cohen, kerrie.cohen@warburgpincus.com

About A-LIGN
A-LIGN is the leading cybersecurity compliance partner, trusted by over 5,700 organizations worldwide to navigate the complexities of compliance, audit, and risk.

With a tech-enabled delivery model and deep domain expertise, A-LIGN has completed more than 31,000 audits. It is the #1 issuer of SOC 2 reports and a top three FedRAMP assessor. Founded in 2009, A-LIGN delivers high-quality, efficient audits across frameworks including SOC 2, ISO 27001, FedRAMP, CMMC, ISO 42001, PCI, and HITRUST. To learn more, visit: https://www.a-lign.com.

About Hg
Hg is a leading investor in European and transatlantic software and services businesses. We help to build sector-leading enterprises that supply critical software applications or workflow services to deliver intelligent automation for their customers.

We take an active approach to value creation, combining deep end-market knowledge with world class operational resources to provide compelling support to entrepreneurial leaders looking to scale enduring businesses.

With a vast European network and strong presence across North America, Hg has more than $85 billion in assets under management and more than 400 employees. Our portfolio spans more than 50 companies worth over $160 billion in aggregate enterprise value, employing more than 126,000 people and consistently growing revenues at more than 20% annually.

About Warburg Pincus
Warburg Pincus LLC is the pioneer of private equity global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles.

Today, the firm has more than $87 billion in assets under management, and more than 220 companies in their active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,000 companies across its private equity, real estate, and capital solutions strategies.

The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit www.warburgpincus.com or follow us on LinkedIn.

Categories: News

Tags:

TEAM Technologies, an Arlington Capital Partners Portfolio Company, Expands Medical Device Manufacturing Capabilities with Acquisition of Duke Empirical, Inc.

TEAM Technologies, an Arlington Capital Partners Portfolio Company, Expands Medical Device Manufacturing Capabilities with Acquisition of Duke Empirical, Inc.

Washington, D.C. and Knoxville, TN – July 7, 2025 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company TEAM Technologies (“TEAM Tech”), a leading end-to-end outsourced manufacturer of mission-critical medical devices, has acquired another leader in the sector, Duke Empirical, Inc (“Duke”). Based in Morgan Hill, CA., Duke is a leading designer, developer and manufacturer of advanced medical devices for interventional cardiovascular applications. Duke specializes in the design and manufacture of innovative catheters and minimally invasive delivery systems.

TEAM Tech works with blue-chip healthcare customers and medical device OEMs to provide end-to-end outsourced design and manufacturing services for critical medical devices, enabling customers to streamline their supply chains and reduce delivery lead times. With synergistic production capabilities and customer bases, the acquisition of Duke will further complement TEAM’s turnkey offering for healthcare and MedTech OEMs, enabling accelerated manufacturing at scale for complex Class II / III medical devices and delivery systems.

“Our investment in TEAM Tech reflects Arlington’s focus on building businesses that deliver mission critical solutions in complex, regulated end markets. The addition of Duke expands TEAM Tech’s ability to serve leading healthcare and MedTech OEMs in the fastest growing segments of the medical device market, while enhancing its capabilities to develop and manufacture highly advanced devices that support the delivery of life saving medical procedures,” said Matt Altman, a Managing Partner at Arlington Capital Partners.

“When we began our partnership with Arlington, we knew we had an opportunity to accelerate our growth and expand our offerings to best serve our clients,” said Marshall White, President and CEO of TEAM Tech. “Duke adds complementary capabilities and greater capacity to our already robust portfolio of full-service medical device manufacturing solutions, and will enable us to provide a greater breadth of complete solutions for our customer partners, who are doing critical, lifesaving work across the healthcare field.”

“The acquisition of Duke enhances TEAM Tech’s capabilities by furthering its expertise in designing and manufacturing advanced interventional cardiovascular products as well as polymer extrusion,” said Gordon Auduong, Managing Director at Arlington Capital Partners. “We are excited to partner with the exceptional team at Duke to deliver TEAM Tech’s entire portfolio of capabilities to further support our customers’ growth.”

Arlington has an extensive track record of building leading companies in highly regulated industries that are critical to the USA’s healthcare infrastructure, government systems and national security. Within healthcare, Arlington focuses on working with businesses that save lives, improve the delivery of products and services and reduce costs for patients and providers. Other notable recent healthcare sector investments the firm has made include Riverpoint Medical, Millstone Medical Outsourcing, Grand River Aseptic Manufacturing, Everest Clinical Research, Afton Scientific and AVS Bio.

Houlihan Lokey served as financial advisor and Goodwin Procter LLP served as legal advisor to TEAM Tech and Arlington Capital Partners.

 

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. The firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. Since its inception in 1999, Arlington has invested in over 175 companies and is currently investing out of its $3.8 billion Fund VI. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.

 

About TEAM Technologies

Headquartered in Knoxville, TN, with facilities throughout the United States and international facilities in Mexico and Singapore, TEAM Technologies is a specialized end-to-end outsourced manufacturer of mission-critical, single-use medical devices. The company has an extensive array of advanced and vertically integrated manufacturing solutions servicing top medical device and pharmaceutical OEMs. With its deep industry experience and reputation for the highest quality standards, TEAM Technologies leverages seamless, turnkey processes and innovation to dramatically simplify and improve its customers’ supply chains. For more information, visit teamtech.com.

 

About Duke Empirical, Inc.

Headquartered in Morgan Hill, CA, Duke Empirical is a leading developer and manufacturer of innovative medical devices focused on advanced catheters and minimally invasive delivery systems. The company specializes in medical device design and development, precision custom extrusion, high performance catheter manufacturing, medical device component assembly, and finished goods assembly and packaging. For more information, visit dukeempirical.com.

 

Contacts

Media Contact

 

Ryan FitzGibbon

Pro-arlington@prosek.com

Categories: News

Tags:

Tikehau Capital raises €1 billion to support Egis’ next phase of growth, with backing from an Apollo S3 / ADIA consortium and Neuberger Berman as co-lead investors

Tikehau

Tikehau Capital, the global alternative asset manager, announces a capital raise for its portfolio company Egis, reaffirming its long-term commitment to supporting the company’s international expansion. This transaction marks the launch of Tikehau Capital’s first private equity continuation fund dedicated to Egis, with a size exceeding €1 billion. The fund aims to support Egis’ growth trajectory and accelerate its global development, particularly through strategic acquisitions. This investment is backed by the second vintage of Tikehau Capital’s flagship private equity decarbonisation strategy, as well as a leading group of investors including as co-lead investors: – – A consortium comprising of Apollo S3 and a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and Neuberger Berman (managed funds on behalf of clients).

This transaction marks the fourth investment made through the second vintage of Tikehau Capital’s private equity strategy dedicated to decarbonisation. With this transaction, the second vintage has surpassed €2 billion in capital raised, just one year after its first closing, reaching a size 1.5 times larger than its predecessor.

Egis is a global leader in architecture, consulting, engineering, construction and mobility services. The company designs, develops and operates smart infrastructure and buildings that address climate change challenges while fostering more balanced, sustainable and resilient development.

Tikehau Capital initially acquired from Caisse des Dépôts et Consignations (CDC) a control position in Egis in January 2022 through the first vintage of its flagship private equity decarbonisation strategy to support Egis’ objectives of executing strategic acquisitions to expand internationally. Egis exceeded the growth targets it set out in 2022 several years ahead of plan; and since then it has more than doubled its EBITDA and exceeded its revenue targets, with revenue surpassing €2.2 billion in 2024.

The capital raise secured via the continuation fund managed by Tikehau Capital should enable Egis to continue this journey and will support its next growth phase, in which the company aims to double its size by 2028 and further solidify its position as a global leader in the decarbonisation of transport, cities and energy. In addition, as part of this transaction, the continuation vehicle also benefits from additional subscription commitments to support future capital increases, supporting Egis with the necessary financial resources to pursue its successful buy-and-build-strategy. CDC remains a key shareholder to support Egis’ development.

Tikehau Capital’s decarbonization strategy focuses on investing in companies at the forefront of global electrification, resource and energy efficiency, low-carbon solutions and climate adaptation. Through this investment strategy, Tikehau Capital continues to support businesses that play a critical role in meeting the growing global energy demand while reducing the carbon footprint of the economy and enhancing its resilience. Mathieu Badjeck and Pierre Abadie, Co-Heads of Tikehau Capital’s Private Equity Decarbonisation Strategy, and Emmanuel Laillier, Private Equity Chief Investment Officer at Tikehau Capital, declared: “Reinvesting in Egis through our second vintage is a natural step in our mission to back transformative companies driving the decarbonisation of the economy. This next chapter of Egis’ growth promises to be even more ambitious, and we are excited to build on its strong momentum, further scaling its impact worldwide. Over the past three years, Egis’ management has demonstrated outstanding leadership, successfully driving rapid expansion, strategic acquisitions and operational excellence. We are thrilled to continue this partnership as Egis seeks to strengthen its position as a global leader in sustainable infrastructure and low-carbon solutions.” Laurent Germain, CEO of Egis, and Olivier Gouirand, CFO of Egis, said: “We are grateful for the continued support of our shareholder, Tikehau Capital. Since 2022, our journey has demonstrated the full potential of a strong collaboration between Egis’ management and the Tikehau Capital private equity team, helping to transform Egis and strengthen its position among industry leaders. Tikehau Capital’s confidence has enabled us to pursue our ambitious strategic plan, “Impact the Future”, with determination – aiming to join the top 10 construction engineering companies and tackle the challenge of decarbonisation. We welcome Apollo S3, ADIA and Neuberger Berman and appreciate their trust. This transaction reaffirms the relevance of our strategy and our ability to achieve our ambitions together with our 20,500 employees. With future investment commitments, Egis will be able to strengthen its capital base and pursue new strategic M&A opportunities, particularly in North America, where we aim to build a platform that matches the scale of the market.”

ABOUT TIKEHAU CAPITAL Tikehau Capital is a global alternative asset management Group with €50.6 billion of assets under management (at 31 March 2025). Tikehau Capital has developed a wide range of expertise across four asset classes (credit, real assets, private equity and capital markets strategies) as well as multi asset and special opportunities strategies. Tikehau Capital is a founder-led team with a differentiated business model, a strong balance sheet, proprietary global deal flow and a track record of backing high quality companies and executives. Deeply rooted in the real economy, Tikehau Capital provides bespoke and innovative alternative financing solutions to companies it invests in and seeks to create long-term value for its investors, while generating positive impacts on society. Leveraging its strong equity base (€3.2 billion of shareholders’ equity at 31 December 2024), the Group invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 750 employees (at 31 March 2025) across its 17 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit: www.tikehaucapital.com.

PRESS CONTACTS: Tikehau Capital: Valérie Sueur – +33 1 40 06 39 30 UK – Prosek Partners: Philip Walters – +44 (0)7773331589 USA – Prosek Partners: Trevor Gibbons – +1 646 818 9238 press@tikehaucapital.com Egis : MAYRAND Isabelle – isabelle.mayrand@egis-group.com – +33 6 17 10 29 70 SHAREHOLDER AND INVESTOR CONTACTS: Louis Igonet – +33 1 40 06 11 11 Théodora Xu – +33 1 40 06 18 56 Julie Tomasi – +33 1 40 06 58 44 shareholders@tikehaucapital.com ABOUT EGIS Egis is a leading global architectural, consulting, construction engineering, operations and mobility services firm. We create and operate intelligent infrastructures and buildings that respond to the climate emergency and contribute to more balanced, sustainable and resilient territorial development. Operating in 100 countries, Egis puts the expertise of its 20,500 employees at the service of its clients and develops cutting-edge innovations accessible to all projects. Through its wide range of activities, Egis is a key player in the collective organisation of society and the living environment of citizens all over the world.

DISCLAIMER The strategy mentioned in this press release is reserved for professional investors and is managed by Tikehau Investment Management SAS, a portfolio management company approved by the AMF since 19/01/ 2007 under the number GP-07000006. Non-contractual document intended exclusively for journalists and media professionals. The information is provided for the sole purpose of enabling them to have an overview of the transactions, whatever the use they make of it, which is exclusively a matter of their editorial independence, for which Tikehau Capital declines all responsibility. This document does not constitute an offer to sell securities or investment advisory services. This document contains only general information and is not intended to represent general or specific investment advice. Past performance is not a reliable indicator of future results and targets are not guaranteed. Certain statements and forecasted data are based on current forecasts, prevailing market and economic conditions, estimates, projections and opinions of Tikehau Capital and/or its affiliates. Owing to various risks and uncertainties actual results may differ materially from those reflected or expected in such forward-looking statements or in any of the case studies or forecasts. Tikehau Capital accepts no liability, direct or indirect, arising from the information contained in this document. Tikehau Capital shall not be liable for any decision taken on the basis of any information contained in this document. All references to Tikehau Capital’s advisory activities in the US or with respect to US persons relate to Tikehau Capital North America.

Categories: News

Tags: